EGFR and non-small cell lung carcinoma: However, these results must be interpreted with caution due to the limited sample size and statistical power of the subgroup analyses, emphasizing the necessity for powered clinical trials to draw definitive conclusions regarding the efficacy of ICIs in EGFR-mutated early NSCLC.